Real-world outcomes in patients with tumor-induced osteomalacia treated vs not treated with burosumab
Journal of the Endocrine Society · 01.08.2026 · 10 (9)
DOI: 10.1210/jendso/bvag165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Endocrine Society, online erschienen am 27.07.2026. Verfasst von María Belén Zanchetta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigaciones Metabólicas (IDIM), Universidad del Salvador, Buenos Aires C1012AAR, Argentina. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kyowa Kirin & Ultragenyx.
Abstract (Originalsprache)
Context
Tumor-induced osteomalacia (TIO) is an ultra-rare condition caused by tumors secreting fibroblast growth factor-23, leading to chronic hypophosphatemia, pain, muscle weakness, fractures, and impaired physical function. Burosumab is a monoclonal antibody indicated for treatment of TIO when tumors cannot be curatively resected.
Objective
This study compares clinical and patient-reported outcomes in patients with TIO treated vs not treated with burosumab in a real-world setting.
Design
This interim analysis reports outcomes at enrollment in the prospective, observational Tumor-Induced Osteomalacia Disease Monitoring Program (NCT04783428), stratified by burosumab treatment status at enrollment.
Setting
Tertiary care centers in the United States and Argentina. Patients Patients with TIO from the Disease Monitoring Program. Exposure Burosumab treatment. Main outcome measure(s) Biochemistry measurements and patient-reported health-related quality of life (pain, fatigue, and physical function).
Results
21 patients with TIO (61.9% female, median [Q1, Q3] age 49.7 years [41.6, 57.3]) were included. At enrollment, 11 (52.4%) patients were treated with burosumab, for a median (Q1, Q3) duration of 4.1 years (0.8, 7.0). Burosumab-treated patients had significantly higher serum phosphate and 1,25-dihydroxyvitamin D levels, and nonsignificantly lower alkaline phosphatase levels, compared with patients not treated with burosumab. Patients treated with burosumab reported significantly lower median Brief Pain Inventory scores, nonsignificantly lower Brief Fatigue Inventory scores, and nonsignificantly higher Patient-Reported Outcomes Measurement Information System Physical Function and Short-Form-36 scores, indicating lower symptom severity and better health-related quality of life.
Conclusion
This study suggests favorable biochemical and patient-reported outcomes in patients with TIO treated with burosumab.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto de Investigaciones Metabólicas (IDIM), Universidad del Salvador, Buenos Aires C1012AAR, Argentina.
- Department of Endocrinology, Vanderbilt University Medical Center, Nashville, TN 37212, USA.
- Departments of Medicine and Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
- Departments of Pediatric (Endocrinology), and Orthopedics and Rehabilitation, Yale University School of Medicine, New Haven, CT 06510, USA.
- Health Economics Outcomes Research, Kyowa Kirin International, Galashiels TD1 1QH, UK.
- Health Economics Outcomes Research, Kyowa Kirin International, Marlow SL7 1HZ, UK.
ORCID-Profile: María Belén Zanchetta, Kathryn M Dahir, Erik A Imel, Thomas O Carpenter, Kerry Sandilands, Ben Johnson, Zhiyi Li, Lucinda Camidge, Elke Rottier, Emma Wilkes, Emily Vinall, Soraya Sader, Suzanne M Jan de Beur
Förderung
- Kyowa Kirin & Ultragenyx
Zitieren
APA
Zanchetta, M. B., Dahir, K. M., Imel, E. A., Carpenter, T. O., Sandilands, K., Johnson, B., Li, Z., Camidge, L., Rottier, E., Wilkes, E., Vinall, E., Sader, S., & Jan de Beur, S. M. (2026). Real-world outcomes in patients with tumor-induced osteomalacia treated vs not treated with burosumab. Journal of the Endocrine Society, 10(9). https://doi.org/10.1210/jendso/bvag165
Vancouver
Zanchetta MB, Dahir KM, Imel EA, Carpenter TO, Sandilands K, Johnson B, et al. Real-world outcomes in patients with tumor-induced osteomalacia treated vs not treated with burosumab. Journal of the Endocrine Society. 2026;10(9). doi:10.1210/jendso/bvag165
BibTeX
@article{Zanchetta2026,
author = {Zanchetta, María Belén and Dahir, Kathryn M and Imel, Erik A and Carpenter, Thomas O and Sandilands, Kerry and Johnson, Ben and Li, Zhiyi and Camidge, Lucinda and Rottier, Elke and Wilkes, Emma and Vinall, Emily and Sader, Soraya and Jan de Beur, Suzanne M},
title = {Real-world outcomes in patients with tumor-induced osteomalacia treated vs not treated with burosumab},
journal = {Journal of the Endocrine Society},
year = {2026},
volume = {10},
number = {9},
doi = {10.1210/jendso/bvag165}
}
EUVIMED